Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparing artificial intelligence and physician performance in predicting IDH mutation status in glioma.

NPJ digital medicine·2026

Same author

Radiomics-based preoperative survival prediction in newly diagnosed glioblastoma: A multicohort study with internal and external validation.

Neuro-oncology advances·2026

Same author

<i>Gliomap-GAN</i>: A conditional generative adversarial network to visualize glioblastoma's cell density from contrast-enhanced magnetic resonance imaging.

Neuro-oncology advances·2026

Same author

Radiomics Analysis of Non-Enhancing Lesions After Bevacizumab Administration in Recurrent Glioblastoma.

Bioengineering (Basel, Switzerland)·2026

Same author

Benchmark Algorithm for Surface Electromyography-Based Periodic Limb Movement Detection.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

Same author

Gyriform infiltration indicates tumor invasion burden of isocitrate dehydrogenase 1/2-wildtype gliomas.

Brain tumor pathology·2025

Same journal

[Current State and Challenges of Digital Health in Japan].

No shinkei geka. Neurological surgery·2026

Same journal

[Emergent Surgery for Brain Tumors].

No shinkei geka. Neurological surgery·2026

Same journal

[Concepts of Cerebrospinal Fluid Management Based on a Paradigm Shift in CSF Dynamics:From the Third Circulation to the Glymphatic System and Meningeal Lymphatic Drainage].

No shinkei geka. Neurological surgery·2026

Same journal

[Management of Severe Traumatic Brain Injury].

No shinkei geka. Neurological surgery·2026

Same journal

[Management of Cerebral Vasospasm in Subarachnoid Hemorrhage].

No shinkei geka. Neurological surgery·2026

Same journal

[Perioperative Management of Spine and Spinal Cord Surgery].

No shinkei geka. Neurological surgery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 15, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

[Astrocytoma, IDH-Mutant].

Hideyuki Arita¹

¹Department of Neurosurgery, Osaka International Cancer Institute.

No Shinkei Geka. Neurological Surgery

|September 24, 2023

Summary

This summary is machine-generated.

This study reviews optimal management for IDH-mutant astrocytoma, a distinct glioma type. Surgical removal extent is increasingly significant for this molecularly defined tumor.

More Related Videos

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Related Experiment Videos

Last Updated: Jul 15, 2025

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Area of Science:

Neuro-oncology
Molecular Pathology
Clinical Neurology

Background:

Astrocytoma, IDH-mutant is defined by IDH1/2 mutation without 1p/19q codeletion per WHO CNS tumor classification.
This molecular definition highlights its relevance, impacting clinical management strategies.
Prior clinical studies often grouped IDH-mutant astrocytoma with other glioma types.

Purpose of the Study:

To discuss optimal management strategies for IDH-mutant astrocytoma.
To analyze recent clinical studies incorporating molecular data for this specific tumor type.
To emphasize the increased importance of surgical resection extent in managing IDH-mutant astrocytoma.

Main Methods:

Review of recent clinical studies focusing on IDH-mutant astrocytoma.
Analysis of molecular diagnostic criteria (IDH mutation, 1p/19q codeletion).
Evaluation of surgical management outcomes in relation to tumor classification.

Main Results:

IDH-mutant astrocytoma is recognized as a distinct molecular and clinical entity.
Optimal management requires consideration of molecular characteristics.
The extent of surgical removal is a critical factor in patient outcomes for this glioma type.

Conclusions:

Management of IDH-mutant astrocytoma should be tailored based on its molecular profile.
Recent molecular analyses are crucial for refining treatment approaches.
Increased emphasis on maximal safe surgical resection is warranted for IDH-mutant astrocytoma.